A Comprehesive Review on Inflammatory Bowel Disease with Homoeopathic Insight

Main Article Content

Dr. Gyanendra Kumar Rai
Prof . (Dr.) Ahijit Chattopadhyay
Dr. Anand Kumar Jaiswal
Dr. Anurag Yadav

Abstract

Ulcerative colitis (UC) and Crohn’s disease (CD) are comprising as chronic inflammatory bowel diseases (IBD), a heterogeneous state of chronic intestinal inflammation with no exact known cause having similar symptoms that lead to digestive disorders and inflammation in the digestive system. The pathogenesis of IBD is complex. Recent studies have greatly improved our knowledge of the pathophysiology of IBD, leading to great advances in the treatment as well as diagnosis of IBD. A number of factors can be attributed to the prevalence of CD and UC, some of which include geographical location, inappropriate diet, genetics, and inappropriate immune response. Conventional therapies are inadequate and are associated with several systemic side effects due to lack to localization of active moiety at the inflamed site. In this review we provide researchers and patients with new insights into this field and facilitate access alongwith hoomeopathic treatments.

Article Details

How to Cite
Dr. Gyanendra Kumar Rai, Prof . (Dr.) Ahijit Chattopadhyay, Dr. Anand Kumar Jaiswal, & Dr. Anurag Yadav. (2023). A Comprehesive Review on Inflammatory Bowel Disease with Homoeopathic Insight. Journal for ReAttach Therapy and Developmental Diversities, 6(1), 2299–2305. https://doi.org/10.53555/jrtdd.v6i1.3385
Section
Articles
Author Biographies

Dr. Gyanendra Kumar Rai

PhD Scholar (Tantia University) BHMS M.D.(Hom)

Prof . (Dr.) Ahijit Chattopadhyay

BHMS M.D.(Hom)

Dr. Anand Kumar Jaiswal

Lecturer State BKHM College & Hospital Deokali, Ayodhya BHMS M.D.(Hom)

Dr. Anurag Yadav

Lecturer, SRHPM State Homoeopathic Medical College & Hospital Barhalganj, Gorakhpur BHMS, MD(Hom)

References

Szigethy E., McLafferty L., and Goyal A., Inflammatory bowel disease, Child and Adolescent Psychiatric Clinics of North America. (2010) 19, no. 2, 301–318, https://doi.org/10.1016/j.chc.2010.01.007, 2-s2.0-77952810795, 20478501.

Stokkers P. C. and Hommes D. W., New cytokine therapeutics for inflammatory bowel disease, Cytokine. (2004) 28, no. 4-5, 167–173, https://doi.org/10.1016/j.cyto.2004.07.012, 2-s2.0-9644252669, 15588691

Mulder, D.J.; Noble, A.J.; Justinich, C.J.; Duffin, J.M. A tale of two diseases: The history of inflammatory bowel disease. J. Crohn’s Colitis 2014, 8, 341–348. [Google Scholar] [CrossRef] [Green Version]

Alatab, S.; Sepanlou, S.G.; Ikuta, K.; Vahedi, H.; Bisignano, C.; Safiri, S.; Sadeghi, A.; Nixon, M.R.; Abdoli, A.; Abolhassani, H.; et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol 2019, 5, 17–30. [Google Scholar] [CrossRef] [Green Version]

Aniwan, S.; Tremaine, W.J.; Raffals, L.E.; Kane, S.V.; Loftus, E.V., Jr. Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study. J. Crohn’s Colitis 2018, 12, 137–144. [Google Scholar] [CrossRef] [PubMed]

Ng, S.C.; Tang, W.; Ching, J.Y.; Wong, M.; Chow, C.M.; Hui, A.J.; Wong, T.C.; Leung, V.K.; Tsang, S.W.; Yu, H.H.; et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013, 145, 158–165. [Google Scholar] [CrossRef] [PubMed]

Kaplan, G.G.; Ng, S.C. Globalisation of inflammatory bowel disease: Perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol. Hepatol. 2016, 1, 307–316. [Google Scholar] [CrossRef]

Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28(2):445–58. doi: 10.1016/s0889-8553(05)70064-9. [DOI] [PubMed] [Google Scholar]Inflammatory Bowel Disease National Action Plan 2019. Available online: https://www.crohnsandcolitis.com.au/site/wp-content/uploads/National-Action-Plan-FINAL-08-03-2019.pdf (accessed on 12 December 2019).

Asakura, K.; Nishiwaki, Y.; Inoue, N.; Hibi, T.; Watanabe, M.; Takebayashi, T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J. Gastroenterol. 2009, 44, 659–665. [Google Scholar] [CrossRef]

Monteleone G., Fina D., Caruso R., and Pallone F., New mediators of immunity and inflammation in inflammatory bowel disease, Current Opinion in Gastroenterology. (2006) 22, no. 4, 361–364, https://doi.org/10.1097/01.mog.0000231808.10773.8e, 2-s2.0-33746263856.

Kaser A., Zeissig S., and Blumberg R. S., Inflammatory bowel disease, Annual Review of Immunology. (2010) 28, no. 1, 573–621, https://doi.org/10.1146/annurev-immunol-030409-101225, 2-s2.0-77952316009, 20192811.

Cummings JF, Keshav S, Travis SP. Medical management of Crohn’s disease. BMJ. 2008;336(7652):1062. doi: 10.1136/bmj.39547.603218.AE. [DOI] [PMC free article] [PubMed] [Google Scholar]

Tremaine WJ. Diagnosis and treatment of indeterminate colitis. Gastroenterology & hepatology. 2011;7(12):826. [PMC free article] [PubMed] [Google Scholar]

Guindi M, Riddell R. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233–44. doi: 10.1136/jcp.2003.015214. [DOI] [PMC free article] [PubMed] [Google Scholar]

Hendrickson BA, Gokhale R, Cho JH. Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clin Microbiol Rev 2002;15:79–94. doi:10.1128/cmr.15.1.79-94.2002

Pasvol TJ, Horsfall L, Bloom S, et al. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open 2020;10:e036584. doi:10.1136/bmjopen-2019-036584

Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1–106. doi:10.1136/gutjnl-2019-318484

Mirkov M. U., Verstockt B., and Cleynen I., Genetics of inflammatory bowel disease: beyond _NOD2_, The Lancet Gastroenterology & Hepatology. (2017) 2, no. 3, 224–234, https://doi.org/10.1016/S2468-1253(16)30111-X, 2-s2.0-85012250195.

Bamias G., Nyce M. R., De La Rue S. A., and Cominelli F., New concepts in the pathophysiology of inflammatory bowel disease, Annals of Internal Medicine. (2005) 143, no. 12, 895–904, https://doi.org/10.7326/0003-4819-143-12-200512200-00007, 2-s2.0-33644873228, 16365470.

Ahern P. P., Schiering C., Buonocore S., McGeachy M. J., Cua D. J., Maloy K. J., and Powrie F., Interleukin-23 drives intestinal inflammation through direct activity on T cells, Immunity. (2010) 33, no. 2, 279–288, https://doi.org/10.1016/j.immuni.2010.08.010, 2-s2.0-77955890952, 20732640.

Richard M. L. and Sokol H., The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases, Nature Reviews Gastroenterology & Hepatology. (2019) 16, no. 6, 331–345, https://doi.org/10.1038/s41575-019-0121-2, 2-s2.0-85062478688, 30824884.

Saleh M. and Elson C. O., Experimental inflammatory bowel disease: insights into the host-microbiota dialog, Immunity. (2011) 34, no. 3, 293–302, https://doi.org/10.1016/j.immuni.2011.03.008, 2-s2.0-79952745080, 21435584.

Hibi T. and Ogata H., Novel pathophysiological concepts of inflammatory bowel disease, The Journal of Gastroenterology. (2006) 41, no. 1, 10–16, https://doi.org/10.1007/s00535-005-1744-3, 2-s2.0-33644500497, 16501852.

Dolan K. T. and Chang E. B., Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases, Molecular Nutrition & Food Research. (2017) 61, no. 1, https://doi.org/10.1002/mnfr.201600129, 2-s2.0-84994666611, 27346644.

Lakatos P. L., Environmental factors affecting inflammatory bowel disease: have we made progress?, Digestive Diseases. (2009) 27, no. 3, 215–225, https://doi.org/10.1159/000228553, 2-s2.0-70349921972, 19786744.

Ho S. M., Lewis J. D., Mayer E. A., Bernstein C. N., Plevy S. E., Chuang E., Rappaport S. M., Croitoru K., Korzenik J. R., Krischer J., Hyams J. S., Judson R., Kellis M., Jerrett M., Miller G. W., Grant M. L., Shtraizent N., Honig G., Hurtado-Lorenzo A., and Wu G. D., Challenges in IBD research: environmental triggers, Inflammatory Bowel Disease. (2019) 25, no. Supplement_2, S13–S23, https://doi.org/10.1093/ibd/izz076, 3109570

Barbara A Hendrickson, Ranjana Gokhale , Judy H Cho ; clinical aspects and pathophysiology of inflammatory bowel disease; Clin Microbiol Rev. 2002 Jan;15(1):79–94.doi: 10.1128/CMR.15.1.79-94.2002 https://pmc.ncbi.nlm.nih.gov/articles/PMC118061/

https://www.researchgate.net/publication/371081983_A_REVIEW_ON_INFLAMMATORY_BOWEL_DISEASE

Gecse KB, Vermeire S: Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol. 2018, 3:644-53. 10.1016/s2468-1253(18)30159-6

Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705.

Shanahan F. Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35. doi: 10.1053/gast.2001.22122

Boericke W. Boericke's New Mannual of Homeopathic Materia Medica with Repertory, Third Revised and Augmented Edition, New Delhi, B Jain Publishers, 2010.

Clarke JH. Dictionary of Practical Materia Medica, Student's Economy Edition, New Delhi, B. Jain Publishers, 1996.

Allen TF. The Encyclopaedic of Pure Materia Medica, New Delhi, B Jain Publishers, 1982.